Coloplast : Uncertainty has gone, resilience stays
>Broader guidance range eliminates uncertainty - There were a lot of speculation about the bottom-line guidance as inflationary headwinds (labour, energy, raw materials) are set to weigh on profitability in 2022-23, while the mid-term guidance consists of an EBIT margin of above 30%. The 2022-23 margin outlook of 28-30% is broader than normal to reflect the higher uncertainty and the elevated input prices. While this is per se not positive, we acknowledge that the unc...Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.